Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30893766 | 1.00 | NPC1 (0.62) | NPC1RAB9APOLBSMN1; SMN2SYK | |
| SCHEMBL784516 | 0.89 | RAB9A (0.62) | NPC1RAB9APOLBSMN1; SMN2ABCB1 | |
| SCHEMBL784068 | 0.88 | RAB9A (0.60) | NPC1RAB9APOLBSMN1; SMN2ABCB1 | |
| SCHEMBL15132062 | 0.86 | MAOB (0.50) | NPC1RAB9ASMN1; SMN2SYKRXRA | |
| SCHEMBL29836285 | 0.85 | LTA4H (0.55) | SMN1; SMN2RXRAMAPTPPIA | |
| SCHEMBL4691988 | 0.85 | LTA4H (0.55) | SMN1; SMN2RXRAMAPTPPIA | |
| SCHEMBL15132074 | 0.84 | KMT2A (0.65) | NPC1RAB9ASMN1; SMN2RXRAKMT2A | |
| SCHEMBL784090 | 0.81 | NPC1 (0.53) | NPC1RAB9APOLBSMN1; SMN2ABCB1 | |
| SCHEMBL17300119 | 0.81 | KMT2A (0.41) | NPC1RAB9ASMN1; SMN2RXRAKMT2A | |
| SCHEMBL17300120 | 0.81 | PPIA (0.63) | KMT2AMAPTPPIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | REJUVERON TELOMERE THERAPEUTICS AG (CH) | 2024-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | DPP9, DPYD, QDPR | NPC1 1249/4885RAB9A 131/4885POLB 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.